Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

5-HT1 agonists described by Merck & Co.

Aug. 9, 1996

Actiq to undergo phase III clinical trials

Aug. 9, 1996

Menarini and Lilly sign comarketing agreement

Aug. 9, 1996

Bifemelane claimed for cerebrovascular disorders treatment

July 26, 1996

Research supports role of testosterone in pathogenesis of stroke

July 26, 1996

Immunex issued U.S. patent for Lerk-7

July 26, 1996

ERT therapy enhances clinical response to tacrine in Alzheimer's patients

July 26, 1996

CP-122638: Pfizer's potential treatment for non-migraine emesis

July 26, 1996

5-HT3/NK1 antagonist combination effective in emesis treatment and prevention

July 26, 1996

Vanderbilt University describes ligands for 5-HT3 receptors

July 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 30, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Taiwan biotech looks outward in next phase of growth
BioWorld
Taiwan’s biotechnology sector was built around domestic health needs, including vaccines and drug manufacturing, but it is increasingly looking outward – to...